Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | HTR7 | P34969 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6429213 | 0.82 | CYP1A2 (0.47) | TSHRSIGMAR1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL10975702 | 0.76 | TSHR (0.71) | TSHRKDM4EHSD11B1SIGMAR1HTT | |
| SCHEMBL19209540 | 0.74 | CHRM2 (0.48) | SIGMAR1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL31420194 | 0.73 | TSHR (0.97) | TSHRKDM4ESIGMAR1NPC1HTR7 | |
| SCHEMBL6947779 | 0.72 | TSHR (0.39) | TSHRKDM4EHSD11B1HTTSMN1; SMN2 | |
| SCHEMBL6431176 | 0.72 | CYP3A4 (0.59) | SMN1; SMN2RAB9ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL12384362 | 0.72 | TSHR (0.45) | TSHRKDM4EHSD11B1HTTCYP2D6 | |
| SCHEMBL10380636 | 0.70 | TSHR (0.63) | TSHRKDM4EHSD11B1SIGMAR1HTT | |
| SCHEMBL6947154 | 0.70 | TSHR (0.43) | TSHRKDM4EHSD11B1SIGMAR1HTT | |
| SCHEMBL5193497 | 0.70 | CYP3A4 (0.61) | SMN1; SMN2MAPTCYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030207919-A1 | Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use | NICOX S.A. (FR) | 2003-11-06 | — | — | US | disclosed |
| US-6593347-B2 | Especially a nitrosated and/or nitrosylated arylpropionic acid, arylacetic acid, enolic anilide or an oxicam | NITROMED, INC. | 2003-07-15 | — | — | US | disclosed |
| US-20020016322-A1 | Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositons and methods of use | NICOX S.A. (FR) | 2002-02-07 | — | — | US | disclosed |
| US-6297260-B1 | Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use | NITROMED, INC. | 2001-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016322-A1 | Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositons and methods of use | NOS2, NOS3, NOS1 | TSHR 2912/4885KDM4E 4320/4885HSD11B1 1013/4885 |
| US-20030207919-A1 | Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use | NOS2, NOS1, NOS3 | TSHR 3326/4885KDM4E 3946/4885HSD11B1 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.